Horizon Europe projects can combine open science with intellectual property (IP) protection. The key is to distinguish what must be made openly accessible, what can legitimately remain restricted, and what should be reviewed before public disclosure. Peer-reviewed scientific publications are subject to mandatory open-access requirements; research data must be managed according to FAIR principles and made openly accessible unless legitimate exceptions apply. At the same time, beneficiaries are expected to consider appropriate protection of results that may be commercially or otherwise exploited.
The practical principle is “as open as possible, as closed as necessary.” It is not a blanket permission to keep results confidential, nor a requirement to publish every piece of project information. Successful projects establish an early, documented process connecting researchers, IP specialists, data stewards and communication teams.
Are open science and intellectual property incompatible in Horizon Europe?
No. Open science governs how research is conducted, shared and made reusable; IP rights govern certain forms of ownership, protection and permitted use. They address different questions and can reinforce one another.
For example, a consortium may file a patent application for a new diagnostic method, publish a peer-reviewed paper through an open-access repository, share a non-sensitive dataset with a suitable licence and keep identifiable patient information restricted. Each decision follows a different legal and operational framework.
A useful distinction is between access and reuse. Making a paper free to read is not identical to giving others permission to reuse it. Similarly, an open-source software licence can authorise broad reuse while preserving copyright. A patent application may secure a priority date before a scientific disclosure, but the filing does not automatically resolve all ownership, confidentiality or international patent issues. For the wider framework, read our guide to exploitation and intellectual property in Horizon Europe.
What open science practices are mandatory under Horizon Europe?
The applicable requirements are set out in the specific grant agreement, especially the provisions on open science and dissemination. The standard Horizon Europe framework distinguishes mandatory practices from recommended ones; particular calls can add requirements.
| Practice | General Horizon Europe position | Practical implication |
|---|---|---|
| Open access to peer-reviewed scientific publications | Mandatory for covered publications arising from the action | Deposit the required version in a trusted repository and provide immediate open access under the required licence |
| Research data management | Mandatory | Establish and maintain a Data Management Plan (DMP), normally by month 6 unless the grant conditions specify otherwise |
| Open access to research data | Required under the principle “as open as possible, as closed as necessary” | Deposit and open relevant data where possible; document justified restrictions |
| FAIR data management | Mandatory principle | Make data Findable, Accessible, Interoperable and Reusable, including appropriate metadata |
| Open access to other research outputs, open peer review, preprints and citizen science | Generally encouraged, not universally mandatory | Choose practices appropriate to the field and check topic-specific requirements |
For publications, beneficiaries must generally deposit a machine-readable electronic copy of the published version or final peer-reviewed manuscript in a trusted repository, at the latest upon publication, and ensure immediate open access. The standard rules normally require a Creative Commons Attribution (CC BY) licence or equivalent; certain exceptions exist, such as for long-text formats. A journal website alone is not necessarily sufficient: repository deposit is a distinct requirement.
For data, open access is not absolute. Confidentiality, protection of personal data, security, legitimate commercial interests and other justified concerns can support restrictions. Even when data cannot be openly shared, metadata and documentation should be made available to the extent appropriate and lawful.
Does Horizon Europe require beneficiaries to protect their results before publishing?
Not every result needs formal IP protection. Beneficiaries must assess whether protection is possible and justified, particularly where it supports exploitation. A publication containing potentially patentable information should therefore be reviewed before disclosure. But open dissemination can be the appropriate strategy for results that do not need exclusive rights.
Consider these distinct decisions:
- Identify the result: Is it a technical invention, software, dataset, method, publication or know-how?
- Confirm ownership and rights: Who generated it? Are there joint owners, third-party rights or background restrictions?
- Assess potential value and risks: Would public disclosure undermine a patent application, confidentiality or exploitation route?
- Select a strategy: Patent, copyright licence, trade-secret protection, design protection, open release or a combination.
- Clear the disclosure: Apply the consortium agreement's review and objection procedures before publishing relevant results.
- Record the decision: Document who approved release, what was disclosed and under which licence.
This process avoids two opposite errors: automatically hiding valuable research and publishing protectable inventions before the necessary review. Our practical guide explains in more detail how to protect intellectual property before publishing Horizon Europe results.
Which intellectual property rights can coexist with open science?
Different rights protect different subject matter. Choosing the right mechanism matters more than applying a generic “IP protected” label.
| Type of result | Possible protection or legal framework | Open-science consideration |
|---|---|---|
| Technical invention | Patent, where patentability requirements are met | Review novelty and filing strategy before enabling public disclosure |
| Software source code | Copyright and an open-source or proprietary licence; sometimes patent rights depending on jurisdiction and invention | An open-source licence grants defined reuse rights; it does not eliminate copyright |
| Scientific article, illustrations or documentation | Copyright and publication licences | Use the licence required by the grant agreement for covered publications |
| Research dataset | Contractual terms, database rights where applicable, confidentiality and data-protection law | Rights in datasets are not automatic or universal; choose licences only where rights permit |
| Valuable confidential know-how | Trade-secret protection if legal conditions and confidentiality measures are satisfied | Public disclosure can destroy secrecy; consider whether a non-confidential summary can be shared |
| Product appearance or branding | Design rights or trademarks where applicable | These rights address different aspects from research-data openness |
Important: Copyright normally arises automatically for qualifying original works; it does not generally require registration in the EU. Conversely, a patent is not automatic and usually requires an application. Publishing a dataset does not necessarily mean the publisher owns every element or can license personal data freely.
Can a Horizon Europe project patent an invention and publish the research?
Yes, patenting and open-access publication can be compatible, but timing and content require careful coordination.
In many jurisdictions, a public disclosure before filing may compromise novelty. A project planning patent protection should obtain specialist advice before submitting a conference abstract, publishing a preprint, releasing code or data, or discussing enabling technical details publicly.
After filing, publication may be possible, but the team should still consider whether the proposed disclosure reveals additional inventions or improvements not covered by the application, affects later filings, conflicts with partner obligations or contains confidential third-party information. Patent protection is territorial, and filing strategies differ by jurisdiction.
Illustrative example: A consortium develops a novel biosensor. Its IP team assesses patentability and coordinates an initial filing covering the relevant technical claims. Researchers then prepare an open-access paper describing validated findings, while the consortium checks that the paper does not reveal unfiled improvements or restricted datasets. A separate dataset is published with appropriate metadata and a reuse licence after privacy and ownership review.
This is a possible strategy, not a universal requirement to patent research results.
How should Horizon Europe projects handle open research data and confidential information?
The Data Management Plan (DMP) should explain what data will be generated or reused, how it will be documented, where it will be stored, whether it can be shared, and why any restrictions are necessary. It should be updated as the project evolves.
A practical decision table helps:
| Data situation | Possible approach | Key safeguard |
|---|---|---|
| Non-sensitive, reusable experimental measurements | Deposit in a trusted repository with rich metadata and an appropriate licence | Check third-party rights and data quality |
| Personal or health data | Assess lawful processing, minimisation and whether sufficiently anonymised data can be shared | Pseudonymisation alone does not remove data from GDPR scope |
| Patent-sensitive technical data | Consider temporary restricted access where justified | Coordinate disclosure with filing and exploitation decisions |
| Confidential industrial partner information | Restrict access or publish a non-confidential derivative | Respect contractual confidentiality and background rights |
| Data that cannot be shared for legitimate reasons | Document the reason and provide appropriate metadata where feasible | Reassess restrictions as circumstances change |
The FAIR principles do not mean that all underlying data must be openly downloadable. Restricted-access data can still be findable and well documented. Likewise, an open licence cannot override privacy law, confidentiality obligations or rights the consortium does not own.
How do dissemination, communication and exploitation differ?
These activities are connected but have different purposes:
- Dissemination shares project results with audiences that may use them, including researchers, practitioners and innovators. Publications, conference presentations and repositories are common channels.
- Communication informs and engages audiences about the action, its activities and its potential or actual benefits. A public-facing article can communicate progress without revealing sensitive technical details.
- Exploitation uses results in further research, products, services, standards, policy or other applications. Exploitation may be commercial or non-commercial.
For example, a press release about a promising diagnostic prototype is communication; a technical journal paper is dissemination; integrating the validated method into a clinical workflow or licensed product is exploitation.
The consortium should coordinate these activities through its dissemination and exploitation planning and the applicable internal clearance process. The Model Grant Agreement and consortium agreement must be checked for notification, objection and protection arrangements: do not assume that every publication is governed by an identical internal deadline. A structured exploitation and dissemination plan helps connect these decisions.
How can a consortium build a workable open science and IP workflow?
A good workflow makes publication decisions predictable without turning every blog post into a legal exercise.
| Stage | Lead responsibility | Decision or record |
|---|---|---|
| Result identification | Work-package leader and researchers | Result description, contributors, possible owners |
| IP and confidentiality screening | IP manager, technology-transfer office or legal adviser | Protection options, third-party rights, confidentiality concerns |
| Data and ethics review | Data steward, ethics and privacy specialists | DMP alignment, data-sharing restrictions, metadata and repository |
| Dissemination clearance | Proposed publisher and consortium partners | Review notices, objections, amendments and approval evidence |
| Publication and licensing | Researchers and communication team | Correct repository, licence, funding acknowledgement and publication record |
| Follow-up | Exploitation lead and coordinator | Uptake, licences, exploitation progress and updated records |
Three practical habits make the process manageable. First, maintain a results register covering ownership, protection status and planned dissemination. Second, put major dissemination milestones on the same calendar as patent decisions and data releases. Third, define who can approve different types of content, including conference abstracts, preprints, public deliverables, software repositories and press releases.
A consortium agreement should clarify ownership and access rights, but it cannot simply override obligations in the grant agreement or applicable law.
What does a balanced strategy look like in a real project?
Consider a fictional Horizon Europe project developing a point-of-care diagnostic platform:
| Output | Proposed approach | Reason |
|---|---|---|
| Novel sensing architecture | Assess patent protection before an enabling disclosure | Preserve a potential route to exploitation |
| Peer-reviewed validation paper | Repository deposit and immediate open access under the applicable licence | Meet scientific publication requirements |
| Patient-level validation data | Restrict identifiable records; consider safely anonymised derivatives | Protect participants and comply with data-protection law |
| Non-sensitive benchmark dataset | Publish with metadata and a suitable licence after rights review | Enable reproducibility and follow-on research |
| Analysis software | Evaluate an open-source licence or another justified model | Match adoption goals and ownership constraints |
| Public project updates | Explain progress, collaborators and potential benefits without disclosing restricted information | Communicate transparently and responsibly |
The important point is not that every result follows the same openness model. It is that each decision is justified, documented and compatible with the project's legal obligations and exploitation objectives.
What mistakes should beneficiaries avoid?
| Common mistake | Why it matters | Better practice |
|---|---|---|
| Treating every open science practice as mandatory | Overstates the grant requirements | Distinguish compulsory, recommended and topic-specific practices |
| Assuming all data must be public | May breach privacy, confidentiality or IP obligations | Apply justified exceptions and document them in the DMP |
| Publishing before patentability review | Can jeopardise novelty and commercial options | Screen enabling disclosures early |
| Assuming a patent filing makes any later publication safe | New technical information may remain unprotected | Review the exact disclosure with IP specialists |
| Confusing free access with unrestricted reuse | Readers' rights depend on the applicable licence | Select and display licences deliberately |
| Assuming all datasets are automatically copyrighted | Legal protection depends on the material and jurisdiction | Check ownership, database rights and contractual permissions |
| Leaving clearance until the day of publication | Creates delays and partner disputes | Build review periods into the dissemination calendar |
Frequently asked questions
Does Horizon Europe require all project results to be open access?
No. The standard rules require open access to covered peer-reviewed scientific publications and establish obligations for research data, subject to legitimate exceptions. Other results may be disseminated under different arrangements, depending on their nature and the applicable grant conditions.
Can we publish a scientific article before filing a patent?
You can, but public disclosure may destroy novelty in jurisdictions relevant to your invention. Seek advice on patentability and filing strategy before disclosing enabling details.
Is open-source software incompatible with commercial exploitation?
No. Open-source software can support commercial products and services, depending on the licence, ownership and business model. Some licences impose obligations when distributing modified software or derivative works.
Must we publish personal research data if the project receives EU funding?
No. Data sharing must respect applicable data-protection law and other legitimate restrictions. Pseudonymised personal data may still be subject to the GDPR; anonymisation must be assessed carefully.
What is the difference between a DMP and an IP strategy?
The DMP describes the management, documentation, preservation, accessibility and reuse of research data. An IP strategy addresses ownership, protection, licensing and exploitation of results. They should be coordinated but are not interchangeable.
Who should approve a conference presentation or public deliverable?
Follow the consortium's dissemination clearance arrangements, including any notification and objection procedures, and involve the relevant result owners or IP specialists when necessary. A public deliverable's classification should also be consistent with the grant's reporting and confidentiality arrangements.
Checklist: Before sharing a Horizon Europe result
- Identify exactly what will become public, including appendices, figures, code and data.
- Confirm ownership, contributors, background rights and any third-party restrictions.
- Screen for potentially patentable or confidential information.
- Check personal data, ethics, security and contractual confidentiality.
- Apply the consortium's notification and clearance procedure.
- Confirm the correct repository, access conditions and reuse licence.
- Include required EU funding acknowledgements and disclaimers where applicable.
- Record the publication or release and update the DMP, results register and exploitation plan as appropriate.
Conclusion: How should Horizon Europe beneficiaries decide what to open and what to protect?
The right balance is not achieved by making everything public or by protecting everything. It comes from choosing an appropriate route for each result, based on legal obligations, scientific value, confidentiality, data protection and intended exploitation.
For Horizon Europe consortia, the most effective approach is an integrated workflow: identify results early, assess protection and sharing options, clear disclosures, publish under the correct conditions and keep decisions traceable. That is how open science and intellectual property can support the same objective: turning publicly funded research into knowledge that others can trust, reuse and build upon.
Official sources and further reading
- European Commission — Horizon Europe: Open Science
- European Commission — Horizon Europe programme guide and reference documents
- European Commission — EU Grants: Annotated Grant Agreement
- European Commission — Horizon Europe Open Science guidance and data management resources
- European IP Helpdesk
- European Open Science Cloud
This article provides general guidance. Always check the applicable call conditions, signed grant agreement, consortium agreement and relevant national or international IP law.